A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.
about
Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategiesSynthetic DNA vaccine strategies against persistent viral infectionsA tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessationTherapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaquesRepeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefitAntibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvantEffect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaquesProlonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge.Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy.Temporal/compartmental changes in viral RNA and neuronal injury in a primate model of NeuroAIDS.
P2860
Q26825814-B7CCAC6E-4E6C-4F0D-A8BD-AEC82E26EC67Q27016078-3A635A1C-D036-4BAE-BC0C-99AF77605EF7Q27319650-0E558458-4096-476C-B070-8DB84E2F1CE9Q28481573-5122149E-30E8-4410-9A61-76552F3CA1E6Q33698152-F45EC21C-B835-4F0C-870A-54D68872FE7DQ33877513-F78997D9-A761-4B65-970F-0E75C3D70D7DQ34596417-489DC3D6-F626-4520-A376-5AD28DB714C9Q35143735-93DD90CE-D051-4E3E-ABBF-6FC913A59BBEQ36164175-71DD20E8-34BE-4ACE-BF4F-8D6E5AD261E9Q37309281-4E3F3150-21C4-4410-A6B9-5894D5BBCE0BQ37325709-095304A6-2BC0-4BE2-BC7F-DD116717D4AFQ39791215-780B3FD0-C3D3-4FDB-B6CD-E8401010F6E7Q54982714-8849D82E-CEAA-4109-AA1D-EDF5DD97CFD8
P2860
A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A therapeutic SIV DNA vaccine ...... c239-infected rhesus macaques.
@ast
A therapeutic SIV DNA vaccine ...... c239-infected rhesus macaques.
@en
type
label
A therapeutic SIV DNA vaccine ...... c239-infected rhesus macaques.
@ast
A therapeutic SIV DNA vaccine ...... c239-infected rhesus macaques.
@en
prefLabel
A therapeutic SIV DNA vaccine ...... c239-infected rhesus macaques.
@ast
A therapeutic SIV DNA vaccine ...... c239-infected rhesus macaques.
@en
P2093
P2860
P356
P1476
A therapeutic SIV DNA vaccine ...... c239-infected rhesus macaques.
@en
P2093
Abigail Bowlsbey
Brigitte Sanders-Beer
Dawn Golightly
Deborah Sites
Diane Hebblewaite
Dietmar Rabussay
Gillis R Otten
Jan zur Megede
Jeffrey B Ulmer
John J Donnelly
P2860
P304
P356
10.1089/AID.2008.0055
P577
2008-08-01T00:00:00Z